Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423430 · ClinicalTrials.gov registry record · NA
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
A NA study of Treatment-Resistant Depression, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06423430: Recruiting NA study of Treatment-Resistant Depression, sponsored by Abbott Medical Devices.
NCT06423430 is a NA study of Treatment-Resistant Depression that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 100 participants, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06423430, a NA study of Treatment-Resistant Depression, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Primary Outcome
The MADRS absolute change is measured as score change from baseline to the endpoint evaluation period. The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.
Conditions Studied
Interventions
- DEVICE Sham-stimulation
- DEVICE Active-stimulation
Study Locations (20)
California
- USC University Hospital - Los Angeles
- UCLA Department of Psychiatry - Los Angeles
- University of California at Davis - Sacramento
Illinois
- Rush University Medical Center - Chicago
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- University of Minnesota Medical Center Fairview - Minneapolis
- Mayo Clinic - Rochester
Ohio
- The Cleveland Clinic Foundation - Cleveland
- The Ohio State University - Columbus
Alabama
- University of Alabama at Birmingham - Dept. of Psychiatry - Birmingham
Florida
- USF Health - Tampa
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2029-04 |
| Phase | NA |
What NCT06423430 shows while recruiting
NCT06423430 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Sham-stimulation is the first listed.
NCT06423430 names 20 study sites across 14 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06423430 about?
NCT06423430 is a clinical study titled "Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)". The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
What is the current status of trial NCT06423430?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-09-11. Estimated completion is 2029-04.
What conditions does trial NCT06423430 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT06423430?
The interventions under investigation include: Sham-stimulation (DEVICE), Active-stimulation (DEVICE).
Who is sponsoring clinical trial NCT06423430?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06423430 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06423430's enrollment target sits among peer trials
100 15th of 54 higher than 37 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
RECRUITING · NA
-
DBS for TRD With the Medtronic Percept PC
RECRUITING · NA
-
PCS in Severe Treatment Resistant Depression
RECRUITING · NA
-
Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder
RECRUITING · NA
-
Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI